Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

Pathogenesis of osteoblastic bone metastases from prostate cancer

(2010) Toni Ibrahim et al.   CANCER

Novel Designs and End Points for Phase II Clinical Trials

(2009) A. A. Adjei et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone

(2009) W. J. Petty et al.   CLINICAL CANCER RESEARCH

Circulating Prostate Tumor Cells Detected by Reverse Transcription-PCR in Men with Localized or Castration-Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival

(2009) P. Helo et al.   CLINICAL CHEMISTRY

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

(2008) Joel B. Nelson et al.   CANCER

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway

(2008) Leticia Oliveira-Ferrer et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Circulating endothelial cells as biomarkers of prostate cancer

(2008) Harry D Georgiou et al.   Nature clinical practice. Urology